Straits Times Index
3,287.22 -0.53 (-0.02%) Nikkei
38,041.28 +412.80 (+1.10%) Hang Seng
17,694.71 +410.17 (+2.37%) FTSE 100
8,078.86 +38.48 (+0.48%) Bitcoin USD
64,340.45 +112.57 (+0.18%) CMC Crypto 200
1,387.79 +5.22 (+0.38%)
Dr. Reddy's Laboratories Limited (RDY)
After hours:
| Previous close | 70.92 |
| Open | 73.40 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's range | 73.27 - 74.33 |
| 52-week range | 53.12 - 77.72 |
| Volume | |
| Avg. volume | 196,456 |
| Market cap | 12.423B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 19.69 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.49 (0.66%) |
| Ex-dividend date | 07 Jul 2023 |
| 1y target est | N/A |
- GlobeNewswire
Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
- Business Wire
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
- Business Wire
Dr. Reddy’s Q3 & 9M FY24 Financial Results
HYDERABAD, India, January 31, 2024--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2023.
